Galectin-3 as a Marker and Potential Therapeutic Target in Breast Cancer

Zhang, Hao; Liu, Xi; Duan, Chao; Liu, Caigang; Zhao, Zuowei

doi:10.1371/journal.pone.0103482

Cited by 61 publications

(60 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In cancer, LEG3 seems to participate to the membrane dynamics of cell migration and in the escaping of the T cells-mediated immune-response [140]. On the basis of its overexpression and of its functions in the breast cancer cells, LEG3 has been recently candidated as biomarker for the triple-negative breast cancer progression [141]. In our tumor samples LEG3, when present, showed a very high expression level, while it was absent in the normal tissues.…”

Section: Galectin Leg3 (Lgals3)mentioning

confidence: 66%

Retrospective Proteomic Screening of 100 Breast Cancer Tissues

Pucci‐Minafra¹,

Cara²,

Musso³

et al. 2017

Preprint

View full text Add to dashboard Cite

Abstract:The present investigation has been conducted on one hundred tissue fragments of breast cancer, collected and immediately cryopreserved following the surgical resection. The fragments were selected from patients with invasive ductal carcinoma of the breast, the most common and potentially aggressive type of mammary cancer, with the objective to increase the knowledge of breast cancer molecular markers, useful for diagnostic and prognostic categorization of patients, in assessing postsurgical therapeutic regimes. The proteomic screening, by 2D-IPG and mass spectrometry, allowed us to identify two main classes of protein clusters: proteins expressed ubiquitously at high levels in all patients, and proteins expressed sporadically among the same patients. Within the group of ubiquitous proteins, glycolytic enzymes and proteins with anti-apoptotic activity were predominant. Among the sporadic ones, proteins involved in cell motility, molecular chaperones and proteins involved in the detoxification appeared prevalent. The data of the present study indicates that the primary tumor growth is generally supported by two concurrent pathways: the inhibition of apoptosis and the stimulation of cellular proliferation. The second phase of the evolution of the tumor can be prematurely scheduled by the occasional presence of proteins involved in cell motility and in the defenses of the oxidative stress. To our knowledge this report on large-scales proteomics of breast cancer is currently a unique approach in the literature that offers the opportunity to evaluate the presence and recurrence of proteins to be used as prognostic indicators and susceptibility to metastasis in patients operated on for invasive ductal carcinoma of the breast.

show abstract

Section: Galectin Leg3 (Lgals3)mentioning

confidence: 66%

Retrospective Proteomic Screening of 100 Breast Cancer Tissues

Pucci‐Minafra¹,

Cara²,

Musso³

et al. 2017

Preprint

View full text Add to dashboard Cite

show abstract

“…Further, to the best of our knowledge, we identify collagen XII for the first time as elevated during post-weaning mammary involution. Importantly, potential roles for each of these highlighted ECM proteins in breast cancer metastasis have been elucidated, with the exception of collagen XII (67–70). While collagen XII has been shown to be upregulated in malignant breast cancer cell lines, and has been identified as a prognostic marker in other cancers, its role in breast cancer progression has yet to be established (71, 72).…”

Section: Discussionmentioning

confidence: 99%

Quantitative extracellular matrix proteomics to study mammary and liver tissue microenvironments

Goddard

Hill

Barrett

et al. 2016

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

Normal epithelium exists within a dynamic extracellular matrix (ECM) that is tuned to regulate tissue specific epithelial cell function. As such, ECM contributes to tissue homeostasis, differentiation, and disease, including cancer. Though it is now recognized that the functional unit of normal and transformed epithelium is the epithelial cell and its adjacent ECM, we lack a basic understanding of tissue-specific ECM composition and abundance, as well as how physiologic changes in ECM impact cancer risk and outcomes. While traditional proteomic techniques have advanced to robustly identify ECM proteins within tissues, methods to determine absolute abundance have lagged. Here, with a focus on tissues relevant to breast cancer, we utilize mass spectrometry methods optimized for absolute quantitative ECM analysis. Employing an extensive protein extraction and digestion method, combined with stable isotope labeled Quantitative conCATamer (QconCAT) peptides that serve as internal standards for absolute quantification of protein, we quantify 98 ECM, ECM-associated, and cellular proteins in a single analytical run. In rodent models, we applied this approach to the primary site of breast cancer, the normal mammary gland, as well as a common and particularly deadly site of breast cancer metastasis, the liver. We find that mammary gland and liver have distinct ECM abundance and relative composition. Further, we show mammary gland ECM abundance and relative compositions differ across the reproductive cycle, with the most dramatic changes occurring during the pro-tumorigenic window of weaning-induced involution. Combined, this work suggests ECM candidates for investigation of breast cancer progression and metastasis, particularly in postpartum breast cancers that are characterized by high metastatic rates. Finally, we suggest that with use of absolute quantitative ECM proteomics to characterize tissues of interest, it will be possible to reconstruct more relevant in vitro models to investigate tumor-ECM dynamics at higher resolution.

show abstract

“…The attenuation of galectin-1 suppressed metastasis in a 4 T1 mouse xenograft breast cancer model [14] and tumor growth in a lung cancer model [16], and also prolonged the survival of glioma-bearing mice [17]. Increased galectin-3 expression has been shown to be associated with the poor prognosis of hepatocellular carcinoma [18], metastasis of renal cell carcinoma [19] and chemoresistance of breast cancer [20]. By contrast, other studies have shown that galectin-3 expression is positively correlated with a favorable prognosis in neuroblastic tumors [21], and the reduction of galectin-3 expression at the invasive front is associated with the invasion and metastasis of colorectal carcinoma [22].…”

Section: Introductionmentioning

confidence: 99%